CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Chongqing Lummy Pharmaceutical Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Chongqing Lummy Pharmaceutical Co Ltd
15F, Building B
Chongqing Academy of Science &Technology
Phone: +86 2367300382p:+86 2367300382 CHONGQING, CHO  401121  China Ticker: 300006300006
Business Summary
Chongqing Lummy Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products are chemical drugs, covering specialty drugs (mainly anti-tumor drugs, digestive system drugs, parenteral nutrition drugs), anti-infective drugs and other products. The Company's main products include nanocarbon suspension injection, clindamycin hydrochloride injection, naloxone hydrochloride injection, indole for injection, tranexamic acid injection, tranexamic acid sodium chloride injection, fludarabine phosphate injection, esomeprazole sodium injection, levofloxacin hydrochloride sodium chloride injection, alanyl-glutamine injection and other products. The Company is also engaged in pharmaceutical distribution business and provides other services.
(Source: F-4)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board JianshengLiang 40 12/1/2021 12/1/2021
Vice Chairman of the Board, Deputy General Manager XuefengLeng 50 3/15/2016 1/1/2007
Chief Financial Officer WenLai 48 3/15/2016 3/15/2016
9 additional Officers and Directors records available in full report.

Business Names
Business Name
300006
Chengdu Jinxing Sanum-Kehibeck Medicine Co., Ltd.
Chongqing Lummy Pharmaceutical Co.,Ltd.

General Information
Number of Employees: 1,019 (As of 12/31/2024)
Outstanding Shares: 1,055,911,205 (As of 12/31/2024)
Shareholders: 34,901
Stock Exchange: SHE
Fax Number: +86 2367300327


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 18, 2025